ClinicalTrials.gg
CompletedNCT03747159SynBioSe-2Updated Oct 7, 2026

Synergetic B-cell Immunomodulation in SLE - 2nd Study.

A Phase 3 interventional study of Belimumab Injection in Lupus Erythematosus, Systemic, sponsored by Leiden University Medical Center. Completed at 4 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Leiden University Medical Center · Phase 3, Interventional, and Treatment

How we know

Updated Oct 7, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
24th of 36
71 · median 81
Started
2018
the only one that year
Phase 3
11 of 36
none open now
Registered
24th of 36
by date
Lead sponsor
2 of 36
Leiden University Medical Center

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 24th largest by enrollment, is the only one that started in 2018, is one of 11 in phase 3, and was the 24th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

In follow-up of the previous SynBioSe Study the present study is a randomized controlled trial designed to further investigate the long-term clinical and imunological efficacy of combination B-cell targeting by starting treatment with belimumab (anti-BAFF) followed by rituximab(anti-CD20) in lupus nephritis patients.

Read the detailed description

Rationale:

The SynBioSe-1 study is the first study to comprehensively describe the clinical and immunological effects of combining rituximab (RTX) and belimumab (BLM) in patients with systemic lupus erythematosus (SLE). From the pioneering SynBioSe-1 study, we have learned that combining RTX+BLM was safe and well-tolerated with important clinical responses. Immunologically, we unexpectedly observed that long-term B-cell depletion was not achieved due to migration of mature B-cells triggered by depletion of BAFF serum levels. The latter observation was in contrast to the study's null-hypothesis that combination therapy would lead to long-term B-cell depletion. The contrary was demonstrated, namely the relative early recirculation of mature B-cells. As such, the immunological and clinical lessons from the SynBioSe-1 study in conjunction with accumulating data from several large studies on combination B-cell targeted treatment have led to the postulation that starting treatment with RTX+BLM would result in an improved B-cell targeting strategy, notably on tissue-resident autoreactive B-cells, associated with improved long-term clinical disease amelioration. Therefore, the present SynBioSe-2 study is designed to further investigate the long-term clinical and imunological efficacy of combination B-cell targeting by starting treatment with belimumab followed by rituximab.

Objectives:

The primary objective is to assess whether combination treatment BLM+RTX will lead to reduced treatment failure and the improvement of pivotal, SLE-specific autoimmune phenomena compared to SLE patients treated with standard of care.

Study design:

a multi-center, randomized, controlled, open-label study

Study population:

SLE patients with a severe flare with major organ involvement or persistent high disease activity despite conventional treatment

Intervention:

In addition to standard therapy, SLE patients will receive self-administered, subcutaneous injections of belimumab every week for the entire study period and 2 infusions of rituximab 1000 mg on day 28 (week 4) and day 42 (week 6).

Main study parameters:

The primary clinical efficacy parameter is the treatment failure rate during the 2 years study period. Secondary endpoints are clinical and non-biased immunological effects of the treatment summarized as follows: reduction of disease relevant autoantibodies, in particular anti-dsDNA autoantibody production at 28 weeks, total renal response rate at 28 weeks, regression of immune complex-mediated excessive neutrophil extracellular traps (NET) formation at 28 weeks; sustained, long-term B-cell depletion during 104 weeks; sustained reduction of relevant anti-nuclear autoantibodies, including seroconversion during 104 weeks; and sustained regression of immune complex-mediated excessive neutrophil extracellular traps (NET) formation during 104 weeks. Additionally, the study will perform safety and toxicity monitoring according to Common toxicity Criteria (CTC) developed by the National Cancer Institute (NCI) with the use of Common Terminology Criteria for Adverse Events (CTCAE) and evaluate the reduction of concomitant immunosuppression and the number of moderate and severe flares during study follow-up.

Study duration: 104 weeks.

Nature and extent of the burden and risks associated with participation and potential benefits:

The study will include SLE patients with a severe flare necessitating remission induction treatment with intensive immunosuppression. The use of belimumab followed by rituximab can ameliorate disease activity even more than conventional treatment in the short-term and contribute to the successful tapering of concomitant immunosuppressive treatment. The latter will possibly lead to the reduction of infectious complication as compared to conventional treatment. The risks are predominantly related to the side effect profile of rituximab and belimumab and infectious complications of long-term B-cell depletion.

03

Conditions studied

  • Lupus Erythematosus, Systemic

Keywords

  • systemic lupus erythematosus
  • lupus nephritis
  • systemic autoimmune disease
  • glomerulonephritis
  • autoimmune glomerulonephritis
  • membranoproliferative glomerulonephritis
  • renal insufficiency
  • renal failure
04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a clinical diagnosis of SLE according to the SLICC criteria 2012
  2. Severe, active SLE disease defined as a situation in which 1 or more of the following criteria are met:

    1. SELENA-SLEDAI (SLE Disease Activity Index) with 12 or more points
    2. New or worse SLE-related activity of major organs, i.e.: CNS-SLE (includes NPSLE), vasculitis, nephritis, pericarditis and/or myocarditis, myositis, thrombocytopenia \< 60, hemolytic anemia \< 4.4mmol/L (=7.0g/dL)
    3. high disease activity that requires or warrants induction treatment by switching to or increasing dosage of oral mycophenolate
  3. New, persisting or progressive disease activity despite the use of conventional maintenance treatment (e.g. mycophenolate or azathioprine)
  4. Positive for relevant SLE-specific autoantibodies defined as a situation in which 1 or more of the following criteria are met:

    1. ANA seropositivity, as defined by a positive ANA-titer ≥ 1:80, before and at screening :

      • Positive test results from 2 independent time points within the study screening period; OR
      • One positive historical test result and 1 positive result during the screening period. Historical documentation of a positive test of ANA (eg, ANA by HEp-2 titer, ANA by ELISA) must include the date of the test.
    2. Anti-DNA seropositivity, as defined by a positive anti-dsDNA serum antibody ≥ 30 IU/mL, before and at screening:

      • Positive test results from 2 independent time points within the study screening period.
      • One positive historical test result and 1 positive result during the screening period. Historical documentation of a positive test of anti-dsDNA (eg, anti-dsDNA by Farr assay or ELISA) must include the date of the test.
  5. Female subjects are eligible to enter the study if she is:

    • Not pregnant or nursing
    • Of non- (i.e. after hysterectomy, , bilateral ovariectomy or documented bilateral tubal ligation or other permanent female sterilization procedure)
    • in agreement to not become pregnant (if female subjects of childbearing potential) and therefore must be sexually inactive by abstinence or use methods with a failure rate of \< 1%.

Exclusion criteria

Exclusion Criteria:

  1. Active pregnancy, as proven by a positive urine beta-HCG test or a positive serum beta-HCG
  2. Significant hypogammaglobulinemia (IgG \< 4.0 g/L) or an IgA deficiency (IgA \< 0.1 g/L)
  3. Immunization with a 1 month before screening
  4. Active infection at time of screening, as follows:

    • Hospitalization for treatment of infection within previous 60 days of day 0 of the study
    • Use of parenteral (intravenous of intramuscular) antibiotics (including anti-bacterials, anti-virals, anti-fungals or anti-parasitic agents) within previous 60 days of day 0 of the study
    • Serological evidence of viral hepatitis defined as: patients positive for HbsAg test or or a positive antibody not treated with antiviral medication
  5. Have a historically positive test or test positive at screening for HIV
  6. Have a history of a primary immunodeficiency
  7. Have a of \< 1.5x10E9/L
  8. Have a significant infection history that in the opinion of the investigator would make the candidate unsuitable for the study
  9. Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies
  10. Have any other abnormal laboratory value in the opinion of the investigator
  11. Have current drugs or alcohol abuse or dependence within 365 days prior to Day 0 of the study
  12. Have an active malignant neoplasm or one in the history of the last 5 years, except basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterine cervix treated locally and with no evidence of disease for 3 years
  13. Have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or any suicidal ideation in the last 2 months or who, in the investigator's opinion, poses a significant suicide risk
  14. Have any other clinically significant abnormal laboratory value, any intercurrent significant medical or psychiatric illness that in the opinion of the investigator would make the candidate unsuitable for the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    BLM+RTX treatment arm

    Intervention 1 Belimumab injection: subcutaneous weekly injections with 200mg belimumab (BML) for the duration of the entire study period of two years. Intervention 2 Rituximab infusion: Two intravenously infusions of 1000mg rituximab (RTX) at week 4 and week 6 after the start of belimumab. Intervention 3: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg\*hour/L.

    Drug: Belimumab Injection

  • No intervention
    Standard of Care treatment arm

    Intervention 1: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg\*hour/L. Optional intervention: (if patients flare or are non-responders on mycofenolate mofetil + prednisolone) : Two intravenously infusions of 1000mg rituximab at week 4 and week 6 after the start of belimumab.

Interventions

  • DrugBelimumabStudies of BelimumabBelimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy

    Also known as: Benlysta subcutaneous injection of 200mg

06

What researchers measure

Primary outcomes

  1. Treatment failure rate

    The treatment failure rate will be measured at 104 weeks in both treatment arms with the hypothesis that lower treatment failure rates will be obtained in the RTX+BLM arm.

    Time frame: 2 years

Secondary outcomes

  1. Change of disease relevant auto-antibodies present at baseline, in particular anti-dsDNA

    All disease relevant auto-antibodies will be measured at 28 weeks and compared to baseline with the hypothesis that a better reduction will be obtained in the RTX+BLM arm.

    Time frame: 28 weeks

  2. Sustained change of autoantibody production

    The sustained reduction of pathogenic autoantibodies, in particular anti-dsDNA autoantibodies

    Time frame: 2 years

  3. Seroconversion of disease relevant auto-antibodies

    Seroconversion of pathogenic autoantibodies, in particular anti-dsDNA autoantibodies

    Time frame: 2 years

  4. Change of memory B-cell numbers

    The detection of (autoreactive) memory B-cells by standardized flowcytometry and in B-cell culture assays

    Time frame: 28 weeks

  5. Sustained change of memory B-cell numbers

    The detection of (autoreactive) memory B-cells by standardized flowcytometry and in B-cell culture assays

    Time frame: 2 years

  6. Change of immune complex-mediated excessive neutrophil extracellular traps (NET) formation

    The quantification of ex vivo NET induction with a 3-dimensional, confocal microscopy technique

    Time frame: 28 weeks

  7. Sustained change of immune complex-mediated excessive neutrophil extracellular traps (NET) formation

    The quantification of ex vivo NET induction with a 3-dimensional, confocal microscopy technique

    Time frame: 2 years

  8. Evaluation of the renal response

    The number of partial and complete renal responders in case of lupus nephritis

    Time frame: 2 years

  9. Evaluation of the clinical response by SLEDAI

    Patients will be monitored at frequent timepoints by the The Systemic Lupus Erythematosus Disease Activity Index 2000 (SELENA-SLEDAI), with a minimum score of 0 and a maximum score of 105, with a higher score indicating a higher disease activity

    Time frame: 2 years

  10. Evaluation of the clinical response by SLICC

    SLICC damage score (System Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus) will be assesed at baseline, one year and two years, with a minimum score of 0 and a maximum score of 47, with a higher score indicating more damage

    Time frame: 2 years

  11. Evaluation of the clinical response by QoL questionnaires

    QoL questionnaires will be assessed at multiple time points by the SF-36 (ShortForm-36) questionnaire, with a minimum score of 0 and a maximum score of 100, with a higher score indicating a higher quality of life

    Time frame: 2 years

  12. Evaluation of the clinical response by the amount of moderate and severe flares.

    Patients will be monitored at frequent timepoints

    Time frame: 2 years

  13. Evaluation of the clinical response by the ability to reduce concomitant immunosuppression without flares

    Patients will be monitored at frequent timepoints

    Time frame: 2 years

  14. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Patients will be monitored at frequent timepoints

    Time frame: 2 years

07

Study locations

4 sites
  • University Medical Center Groningen
    Groningen, 9713 GZ, Netherlands
  • Leiden University Medical Center
    Leiden, 2333 ZC, Netherlands
  • Radboud University Medical Center
    Nijmegen, 6525 GA, Netherlands
  • HagaZiekenhuis
    The Hague, 2545 AA, Netherlands
08

References and documents

Publications

  • Arends EJ, Zlei M, Tipton CM, Cotic J, Osmani Z, de Bie FJ, Kamerling SWA, van Maurik A, Dimelow R, Gregan YI, Fox NL, Rabelink TJ, Roth DA, Sanz I, van Dongen JJM, van Kooten C, Teng YKO. Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2024 Sep 1;63(9):2387-2398. doi: 10.1093/rheumatology/keae286. PubMed 38775637 ↗
  • van Schaik M, Arends EJ, Soonawala D, van Ommen E, de Leeuw K, Limper M, van Paassen P, Huizinga TWJ, Toes REM, van Kooten C, Rotmans JI, Rabelink TJ, Teng YKO. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial. Trials. 2022 Nov 12;23(1):939. doi: 10.1186/s13063-022-06874-w. PubMed 36371234 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Jun 2026, 92 months.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 92 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2024 → Jun 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2018
First posted
Nov 20, 2018
StartActual
Oct 1, 2018
Primary completionActual
Jun 22, 2026was Jun 2024
CompletionActual
Jun 22, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 7, 2026
Primary completion
Jun 7, 2024→Jun 22, 2026
Oct 7, 2026
Study completion
Jun 7, 2026→Jun 22, 2026 (actual)
Oct 7, 2026
Enrollment
70 (estimated)→71 (actual)
Oct 7, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedSELENA-SLEDAI-2K (SLE Disease Activity Index) with 12 or more points
Oct 7, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38775637 ↗
Oct 7, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionEvaluation of the clinical response by SLEDAI: how it is measured was reworded
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38775637 ↗
    Primary completion Jun 7, 2024→Jun 22, 2026
    Study completion Jun 7, 2026→Jun 22, 2026 (now actual)
    Enrollment 70 (estimated)→71 (actual)
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedSELENA-SLEDAI-2K (SLE Disease Activity Index) with 12 or more points
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionEvaluation of the clinical response by SLEDAI: how it is measured was reworded
    + 5 other changes: identifiers, verification date, oversight details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03747159
Collaborators
Dutch Kidney Foundation, GlaxoSmithKline
Responsible party
Y.K.Onno Teng (Dr. Y.K.O. Teng, Nephrologist, Leiden University Medical Center) — Principal investigator
First posted
Nov 20, 2018
Start date
Oct 1, 2018
Primary completion
Jun 22, 2026
Completion
Jun 22, 2026
Last update
Oct 7, 2026

Study contacts

Dr. Y.K.O. Teng, MD, PhD
principal investigator · Leiden University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion